Welcome to our dedicated page for N2OFF news (Ticker: NITO), a resource for investors and traders seeking the latest updates and insights on N2OFF stock.
N2OFF Inc delivers innovative agri-food tech solutions focused on plant-based food safety and sustainable supply chains. This news hub provides investors and industry stakeholders with timely updates on the company’s advancements in food technology, environmental initiatives, and strategic partnerships.
Access official press releases covering earnings reports, operational milestones, and sustainability achievements. Our curated collection ensures transparent tracking of N2OFF’s integrated approach to agricultural innovation, quality assurance, and eco-conscious production practices.
Explore updates on subsidiary developments, regulatory compliance advancements, and collaborations shaping the future of plant-based food systems. Bookmark this page for streamlined access to verified information supporting informed analysis of N2OFF’s market position and industry contributions.
N2OFF (NASDAQ: NITO) completed the acquisition of MitoCareX and published a shareholder letter outlining MitoCareX’s strategy, milestones, and pipeline powered by its proprietary MITOLINE™ algorithm.
MitoCareX reports it has identified promising hit compounds with measurable biological activity against a mitochondrial SLC25 transport protein linked to aggressive cancers, and plans hit-to-lead optimization, PK profiling, and nomination of a preclinical development candidate in 2026. Management is pursuing licensing and collaborations to generate non-dilutive revenue and aims to prepare for IND-enabling studies while positioning MITOLINE™ as a scalable discovery engine.
N2OFF (NASDAQ: NITO) completed its acquisition of MitoCareX on October 20, 2025, making MitoCareX a wholly owned subsidiary following satisfaction of closing conditions under a February 25, 2025 securities purchase and exchange agreement.
Transaction details include a $700,000 cash purchase of shares from SciSparc, issuance of N2OFF common stock representing 40% of fully diluted capital to MitoCareX sellers, seller rights to 30% of financing proceeds (capped at $1.6M) for five years, and milestone-based issuances up to 25% of common stock. N2OFF committed to fund MitoCareX operations for the first two post-close years. MitoCareX focuses on mitochondrial SLC25 targets and a computational platform called MITOLINE for small-molecule discovery in hard-to-treat cancers.
N2OFF (NASDAQ: NITO) closed its acquisition of MitoCareX on October 20, 2025, making MitoCareX a wholly owned subsidiary focused on drug discovery targeting mitochondrial SLC25 proteins and hard-to-treat cancers including pancreatic and non-small cell lung cancer.
N2OFF paid $700,000 to SciSparc for MitoCareX shares and issued N2OFF common stock representing 40% of fully diluted capital to the sellers. Sellers are entitled to 30% of financing proceeds (capped at $1.6M) for five years and up to 25% additional common stock
N2OFF (NASDAQ: NITO) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq confirmed on October 6, 2025 that N2OFF's American Depositary Shares closed at $1.00 or greater for 10 consecutive business days (September 22, 2025 to October 3, 2025), closing the prior deficiency. The company had been notified of non-compliance on March 28, 2025 after ADSs traded below $1.00 for more than 30 consecutive business days. N2OFF is a cleantech investor using the RTB (Ready to Build) model, lead investor in four EU solar projects across three countries, and controls ~98% of Save Foods, a post-harvest treatments company.
N2OFF (NASDAQ: NITO) shareholders have approved the acquisition of MitoCareX Bio Ltd., transforming the company from a cleantech solar energy firm into a biotech focused on cancer therapeutics. The deal structure includes a $700,000 cash payment to SciSparc and share exchanges resulting in sellers receiving 40% of N2OFF's fully diluted capital stock.
MitoCareX specializes in developing treatments for resistant cancers by targeting the mitochondrial SLC25 protein family, utilizing 3D modeling and in-vitro screening systems. The transaction includes milestone-based stock issuances of up to 25% additional shares and commits N2OFF to invest $1 million initially in MitoCareX's operations. The deal is expected to close in early October 2025.
N2OFF (NASDAQ: NITO) has announced a 1-for-35 reverse stock split effective September 22, 2025. The move aims to regain compliance with Nasdaq's continued listing requirements and attract institutional investors. Following the split, the company's outstanding shares will decrease from approximately 33 million to 953 thousand shares.
The reverse split was previously approved by stockholders at a Special Meeting on June 28, 2024. The company's stock will continue trading under the symbol "NITO" with a new CUSIP number 80512Q501. Proportionate adjustments will be made to outstanding options and warrants, and fractional shares will be rounded up to the next whole share.
N2OFF (NASDAQ: NITO) reported significant progress in its European solar and energy storage initiatives. The company's flagship project in Melz, Germany includes a 115 MWp solar PV facility and a 107 MW/214 MWh battery storage system, with RTB status expected by 2026. The project received municipal approval and secured grid connection through E.dis.
In Italy, N2OFF holds a 70% stake in two Battery Energy Storage Systems in Sicily, each with 98 MWp/392 MWh capacity. Both projects have received connection approval from Terna SpA and are expected to reach RTB status by mid-2027. The company provided €600,000 in debt financing for the Melz BESS integration, featuring a 7% annual interest rate and 25% profit-sharing agreement.
N2OFF (NASDAQ: NITO) announced the expansion of its Melz solar project in Germany with a significant battery storage component. The company will provide additional debt financing to Solterra Renewable Energy for integrating a 107 MW / 214 MWh battery energy storage system (BESS) into its existing 115 MWp solar photovoltaic project.
The financing includes a €600,000 loan at 7% interest, with N2OFF entitled to 25% of potential profits after loan repayment. According to Entrix's analysis, the BESS integration could increase project revenues by 40-50%, generating additional income of €100-120 per MW annually through load shifting and ancillary services.
The Melz project, expected to receive final plan approval in early 2026, is part of N2OFF's broader renewable energy partnership with Solterra, which includes multiple BESS projects across Europe.
N2OFF (NASDAQ: NITO) has completed the second installment of a $2.7 million investment for two Battery Energy Storage Systems (BESS) in Sicily, Italy. The company has invested $1.2 million to date through its 70%-owned Italian subsidiary for the development of two 98MWp/392MWh BESS facilities.
The projects, with a combined capacity of 196 MWp, are estimated to be worth up to $13.5 million based on an industry valuation of $70,000 per MW. The BESS projects have received preliminary grid connection approvals from Terna SpA and are expected to achieve Ready-to-Build (RTB) status within 18-24 months.
FAQ
What is the current stock price of N2OFF (NITO)?
What is the market cap of N2OFF (NITO)?
